Eligible patients with BP I 7-17 years old (n~60) (n~ 60) responders and partial responders

**Pharmacokinetic Phase** (8 weeks of open label lithium (Li⁺) treatment)

- YMRS reduction < 25% or CGI-I ≥ 4 and are not able to tolerate at least 600mg/day
- All other subjects

**Long-Term Effectiveness Phase** (16 weeks of open label Li⁺ treatment)

- Completes at least 6 of the last 8 consecutive weeks (including week 15 and 16 of the phase) with complete remission of psychotic features and a remission of mood symptoms (YMRS < 10 and CDRS-R <35)

**Discontinuation Phase** (Patients randomized to either placebo (PCB) or Li⁺ for 28 weeks of treatment)

- No Mood Relapse
  - Complete Study
- Mood Relapse
  - Restabilization Phase (8 weeks of open label Li⁺ treatment)